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Abstract
Introduction—Respiratory therapists and other healthcare workers are potentially exposed to a 
variety of aerosolized medications. The NIOSH Health and Safety Practices Survey of Healthcare 
Workers describes current exposure control practices and barriers to using personal protective 
equipment during administration of selected aerosolized medications.
Methods—An anonymous, multi-module, web-based survey was conducted among members of 
healthcare professional practice organizations representing respiratory therapists, nurses and other 
healthcare practitioners. A module on aerosolized medications included submodules for antibiotics 
(amikacin, colistin, tobramycin), pentamidine and ribavirin.
Results—The submodules on antibiotics, pentamidine and ribavirin were completed by 321, 227 
and 50 respondents, respectively, who were mostly respiratory therapists. The relatively low 
number of ribavirin respondents precluded meaningful interpretation of these data and may 
represent the rare use of this drug. Consequently, analysis focused on pentamidine, classified by 
NIOSH as a hazardous drug, and antibiotics amikacin, colistin, and tobramycin which currently 
lack authoritative safe handling guidelines. Respondents who administered pentamidine were 
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more likely to adhere to good work practices compared to those who administered these 
antibiotics. Examples included: training received on safe handling procedures (75% vs 52%), 
availability of employer standard procedures (82% vs 55%), use of aerosol delivery devices 
equipped with an expiratory filter (96% vs 53%) or negative pressure rooms (61% vs 20%), and 
always using respiratory protection (51% vs 13%).
Conclusions—Despite the availability of safe handling guidelines for pentamidine, 
implementation was not universal, placing workers, co-workers, and even family members at risk 
of exposure. Although the antibiotics included in this study lack authoritative safe handling 
guidelines, prudence dictates that appropriate exposure controls are used to minimize exposure to 
the antibiotics as well as other aerosolized medications. Employers and employees share 
responsibility for ensuring that precautionary measures are taken to keep exposures to all 
aerosolized medications as low as practicable.
Keywords
aerosolized medications; respiratory therapists; exposure controls; pentamidine; antibiotics; web-
based survey
INTRODUCTION
Aerosolized medications are used to treat respiratory infections and other pulmonary 
ailments via inhalation therapy. Nebulizers are commonly used to deliver a fine spray or 
mist containing one or more medications which can be directly inhaled from the mouthpiece 
of the device.1 Aerosol generators have also been used to treat pediatric patients (e.g., 
ribavirin) inside containment hoods or tents. Aerosolized medications may be preferred over 
systemic therapy for several reasons: the medication can be delivered to a specific site, 
lower dosage can achieve high drug concentrations in the lungs, and the potential for 
systemic side effects are reduced.2, 3 Despite their inherent benefits, aerosolized medications 
may pose an occupational hazard to respiratory therapists and other healthcare workers who 
administer them. Unintentional inhalation of fugitive aerosols can occur when the nebulizer 
mouthpiece or mask is improperly fitted or separated from the patient’s mouth (e.g. 
coughing).4–6 Although exposure to aerosolized medications among caregivers is relatively 
low compared to the patients receiving treatment, adverse effects in occupationally exposed 
workers have been reported. 1, 7
The following aerosolized medications were included in this study: antibiotics (amikacin, 
colistin, tobramycin); anti-protozoal (pentamidine), and anti-viral (ribavirin). The targeted 
aerosolized antibiotics have been associated with respiratory irritation, ototoxicity and 
nephrotoxicity (amikacin); rhinitis, asthma and dyspnea (colistin); and eye irritation and 
asthma-like symptoms (tobramycin). 8–10 Primary health effects associated with 
occupational exposure to pentamidine include dyspnea, chest tightness, cough, 
conjunctivitis, hematologic abnormalities, perinasal paresthesia and numbness. 11, 12 
Aerosolized pentamidine also has been shown to be embryotoxic in animals.13 Respiratory 
irritation, shortness of breath, ocular irritation, asthma, and skin rash have been reported by 
healthcare workers administering aerosolized ribavirin.14 Ribavirin has also been shown to 
be teratogenic (in rodents) which has prompted precautionary guidelines for healthcare 
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workers of child-bearing age.15 Evidence of pentamidine and ribavirin exposure has been 
detected in the urine of exposed healthcare workers.4, 16, 17 Surveys of respiratory therapists 
have reported an increased risk of occupational asthma and other respiratory 
symptoms.18, 19,20
The National Institute for Occupational Safety and Health (NIOSH) and the Occupational 
Safety and Health Administration (OSHA) consider pentamidine and ribavirin hazardous 
drugs and have developed guidelines for the safe handling of both medications.15, 21 These 
guidelines provide information on recommended exposure controls to protect healthcare 
workers from exposure and adverse health effects. Unless a hazard can be eliminated or 
substituted by a substance less toxic (which is not feasible with respect to aerosolized 
medications), exposure controls should be systematically implemented in the following 
decreasing order of efficacy: 1) engineering controls, 2) administrative controls, 3) work 
practice controls, 4) personal protective equipment (PPE).22 Authoritative guidelines for 
safe handling of the targeted aerosolized antibiotics do not exist; they have not been linked 
to serious health effects.
Training and standard procedures, often part of a comprehensive health and safety program, 
are important for reducing exposure to aerosolized medications.23 A NIOSH Alert 
recommends the implementation of such a program for handling hazardous drugs.21 
Additionally, the American Society of Health-System Pharmacists (ASHP) guidelines state 
that only trained workers should administer hazardous drugs.24 Standard procedures should 
stipulate the use of appropriate engineering and administrative controls and PPE to minimize 
exposure of healthcare personnel to aerosolized medications during treatment of 
patients. 5, 24 Engineering controls are effective at removing fugitive aerosols at the 
source.25 These may include continuous aerosol delivery systems equipped with expiratory 
filters or ventilated booths equipped with HEPA filters.1, 5 Multiple engineering controls 
including the use of negative pressure rooms in combination with these devices may also be 
used to further protect healthcare workers.
The primary objective of this study was to describe self-reported work practices of 
respiratory therapists and other healthcare workers who administer aerosolized amikacin, 
colistin, tobramycin, pentamidine, and ribavirin. This national survey is the first to examine 
use of engineering, administrative and work practice controls and PPE by healthcare 
workers administering the targeted aerosolized medications.
METHODS
Survey Methodology
Data used in this study are from the NIOSH Health and Safety Practices Survey of 
Healthcare Workers, an anonymous, multi-module, web-based survey conducted from 
January 28 through March 29, 2011. The study population included members of professional 
practice organizations representing healthcare occupations which routinely use or come in 
contact with several classes of chemical agents prominently found in healthcare. Practices 
around the administration of aerosolized medications were addressed by one of seven hazard 
modules targeted to members of the American Association for Respiratory Care, the largest 
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professional practice organization representing respiratory therapists. Other healthcare 
workers who administered aerosolized medications were also invited to complete the survey 
module. Methods used in the design, testing, and implementation of the survey, and 
strengths and limitations were described elsewhere.26
Survey Instrument
The hazard module addressing aerosolized medications consisted of three submodules: 1) 
antibiotics amikacin, colistin, tobramycin; 2) pentamidine, and 3) ribavirin. The topic areas 
covered by this module can be found in the online supplement. The submodules for 
antibiotics and pentamidine contained 29 questions each, while the submodule for ribavirin 
contained 31 questions. Question format included yes/no, multiple choices and multiple 
options (check all that apply). In cases where responses were not exhaustive, respondents 
could select “other” and type in a response.
The modular survey was programmed to present the most relevant hazard module first based 
on screening questions, then the core module, and then a second hazard module, if indicated. 
It was possible for respondents to complete the aerosolized medications module and not the 
core module. In those cases, demographic information is unavailable.
Data Analysis
Data were analyzed using SAS 9.3 (Cary NC: SAS Institute, Inc). Simple frequencies and 
prevalences are presented for questions in the aerosolized medications submodules and 
selected questions in the core module that describe demographic, employer and occupation 
characteristics. We compared responses from all respondents and from respiratory therapists 
to questions addressing training, availability of employer procedures, use of aerosol delivery 
equipment/engineering controls, and use of PPE to determine if prevalence changed 
substantively; because no differences were observed, the data for all respondents are 
reported. Either the Pearson chi-square test or the Fisher’s exact test (at least one cell with 
an expected value <5) was used to assess differences in healthcare practices between 
antibiotics and pentamidine.
The time frame for most questions on aerosolized antibiotics and ribavirin was “the past 7 
calendar days,” while for pentamidine, it was “the past 30 calendar days.” A longer time 
period for pentamidine was used to maximize the number of respondents because it was 
administered less frequently than the other medications, based on input from practitioners. 
For a question addressing use of engineering controls, the survey was programmed to 
present two response scenarios: “yes” or “no” when the aerosolized medication was 
administered only one time in the past 7 calendar days, or “every time,” “sometimes,” or 
“never,” when administered more than one time. For analysis, frequencies of “yes” and 
“every time” and “sometimes” were combined as “yes” responses; frequencies of “no” and 
“never” were combined as “no” responses. Additionally, respondents were asked to select 
reason(s) for not always using each of four types of PPE (i.e., protective gloves, water-
resistant gowns or outer garment, eye/face protection, and respirator). Each reason for not 
always wearing PPE was subsequently summarized across all four types of PPE. The 
percentage of respondents was obtained by calculating the number of respondents who did 
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not always use any one of the four types of PPE due to a specified reason divided by the 
total number of respondents (including those who reported always wearing PPE). Each 
respondent was counted once for each reason, even if the same reason was given for more 
than one type of PPE. Age of respondent was estimated by subtracting year of birth from the 
year the survey was administered. States where respondents worked were aggregated into 
four U.S. Census regions (Northeast, Midwest, South and West) for reporting purposes. 
Because the primary intent of this survey was to provide descriptive information on 
precautionary practices around administration of aerosolized medications, no a priori 
hypotheses were proposed.
Human Subjects Review
The NIOSH Institutional Review Board determined that the activities in this project were 
surveillance and did not meet the criteria of research according to 45 CFR 46.1101(b)(2) and 
CDC guidelines for defining public health research and public health non-research.27
RESULTS
Respondent Characteristics
A total of 491 respondents completed one or more submodules of the aerosolized 
medications hazard module. Submodules on antibiotics, pentamidine, and ribavirin were 
completed by 322, 231, and 50 respondents, respectively. The core module was completed 
by 285 (89%), 201 (89%) and 40 (80%) of these respondents, respectively, and can be 
characterized by demographic data. The relatively low number of respondents to the 
ribavirin submodule precludes meaningful interpretation of the data; therefore, no additional 
data on ribavirin practices will be presented. We provide descriptive information on 
respondent demographic and administration characteristics for aerosolized antibiotics and 
pentamidine in Online Supplemental Tables 1 and 2.
Demographic, occupation and employer characteristics for respondents of the antibiotics and 
pentamidine submodules were similar with respect to many characteristics (Online 
Supplemental Table 1). Most respondents of the antibiotics and pentamidine submodules 
were female (65%, 70% respectively), white (88%, 91%), over 40 years of age (83%, 88%), 
possessed at least an associate’s degree (92%, 92%), spent over 50% of their time in direct 
patient care (82%, 72%), had 11 or more years in their current occupation (79%, 81%) and 
with their employer (55%, 64%), and did not belong to a labor union (90%, 89%). 
Respiratory therapists represented 87% and 76% of the antibiotics and pentamidine 
submodules, respectively; with nurses comprising most of the remaining respondents. 
Employers were best characterized as hospitals having >1,000 employees (>56%), non-
profit (>61%), located in a large city (>65%), and fairly equally distributed across four U.S. 
geographical regions.
Administration Characteristics
Antibiotics and pentamidine administration characteristics are presented in Online 
Supplemental Table 2. Administration practices of respondents to the antibiotics submodule 
were best characterized as follows: 70% administered for six or more years; 85% 
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administered three or fewer days in the past seven days; nearly 70% administered fewer than 
four times in the past seven days; over 60% spent fewer than 15 minutes with a patient 
during a single administration; and over 90% delivered aerosol therapy in patient’s hospital 
rooms. Administration practices of respondents to the pentamidine submodule were best 
characterized as follows: over 70% administered for six or more years; 75% administered no 
more than two days in the past 30 days; over 90% administered only up to five times in the 
past 30 days; over 60% spent 15 minutes or more with a patient during a single 
administration; and nearly 75% administered the medication in a clinic/department treatment 
room or area. Respondents administered pentamidine for more years and spent more time 
with patients per treatment than respondents who administered antibiotics. Both respondent 
groups reported that the number of times they had administered the medication was about 
the same as usual.
Training and Employer Standard Administration Procedures
Respondents were much less likely to receive training on the safe handling of antibiotics 
than pentamidine (52% vs 75%; P < 0.01) (Table 1). This difference was further magnified 
(45% vs 75%; P <0.01) when respondents who administered both antibiotics and 
pentamidine were excluded from the analysis. However, of those who had received training, 
a slightly higher proportion of pentamidine respondents (66% vs 59%; P= 0.21) reported 
being trained more than 12 months ago. Respondents administering antibiotics also reported 
their employer was less likely to have standard administration procedures compared to those 
who administered pentamidine (55% vs 82%; P < 0.01).
Use of Aerosol Delivery Equipment and Engineering Controls
In some cases, the aerosol delivery equipment and engineering controls were unique to one 
medication (e.g., ventilated booth or treatment station equipped with a high efficiency 
particulate air (HEPA) filter for pentamidine). In other cases, the same devices/controls were 
applicable to both medications (e.g., negative pressure room, nebulizer with expiratory 
filter) and comparisons were made. Where the same controls/devices were used, 80% of 
respondents administering antibiotics and nearly 40% of respondents administering 
pentamidine never used a negative pressure room (P < 0.01). Additionally, nearly half (47%) 
of the respondents administering antibiotics never used a hand-held, continuous aerosol 
delivery system with an expiratory filter compared to only 4% of pentamidine respondents 
(P < 0.01). About 46% of respondents administering pentamidine never used a ventilated 
booth or treatment station equipped with a HEPA filter. For engineering controls unique to 
antibiotics, nearly 60% of respondents never used a ventilator equipped with an expiratory 
HEPA filter, and 48% never used a continuous aerosol delivery system attached to a face 
mask, face tent or tracheostomy collar (Table 2).
Personal Protective Equipment
Frequency of use and reasons for disuse—Respondents of both antibiotics and 
pentamidine submodules reported that they did not always use protective gloves (21% vs 
22%; P = 0.79) and water-resistant gowns or outer garments (66% vs 69%; P= 0.47). Nearly 
88% respondents administering antibiotics did not always use eye/face protection or 
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respirators. By comparison, a smaller proportion of respondents administering pentamidine 
did not always use respirators (49%; P < 0.01) or eye/face protection (75%; P < 0.01) (Table 
3). Approximately 90% of respondents of both submodules who used a respirator reported 
that they were fit-tested.
Respondents who reported that they did not always wear PPE when administering 
antibiotics and pentamidine were asked to select from a list of 10 reasons (including “other, 
please specify”) all applicable reasons for not always wearing PPE (Table 4). The reason 
most reported by respondents was “not part of our protocol”. Statistically significant 
differences between those administering antibiotics and those administering pentamidine 
were found for the following reasons: “an engineering control was being used” (P <0.01), 
“not part of our protocol” (P <0.01), “no one else who does this work uses them” (P <0.01), 
“not provided by employer (P=0.02), “not readily available in work area” (P=0.01), and 
“Other” (P=0.01). Other reasons primarily included “never trained to wear gloves/gowns” 
and “not aware gloves or gowns were needed.” Please see Online Supplemental Table 3 for 
results separated by type of PPE.
Glove use: activities where cross-contamination may occur (done while 
wearing gloves that were used to handle medications)—Four percent of 
respondents who administered pentamidine and 3% of respondents who administered 
antibiotics reported that they had removed and later re-used gloves that had been worn 
during treatments (P=0.72) (Table 5). Respondents were also asked whether they performed 
selected activities while wearing gloves that had been used during administration. Activities 
most frequently reported by respondents who administered pentamidine included “touch 
door knobs, cabinets, or drawers” (41%), “use pens/pencils” (36%), and “use a non-
disposable stethoscope” (36%). Activities most frequently reported by respondents who 
administered antibiotics included “touch I.V. pump or bed controls” (54%), “touch door 
knobs, cabinets, or drawers” (52%), and “use pens/pencils” (51%). Respondents who 
administered antibiotics reported higher frequencies for all activities with the exception of 
“handle files or charts.”
Took home clothing—Sixty percent (n=175) of respondents administering antibiotics 
and 43% (n=85) of respondents administering pentamidine took home clothing that came in 
contact with these medications (P <0.01), additionally, 12% and 16%, respectively, did not 
know whether they had.
Exposure Monitoring
Exposure monitoring (i.e., air and/or surface wipe sampling) was not common. Only 9% of 
respondents reported that monitoring had been conducted by their employer for pentamidine 
and a few percent for the antibiotics tobramycin and colistin. Amikacin was not included as 
a response option because it lacked a monitoring method. Approximately 40% of 
respondents reported that they did not know whether monitoring had been done for 
pentamidine or the two antibiotics.
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The NIOSH Health and Safety Practices Survey of Healthcare Workers is the first national 
survey to describe self-reported use of safe handling precautions by respiratory therapists 
and other healthcare workers who administer aerosolized medications. This study provided 
an opportunity to compare exposure control practices for a hazardous drug (pentamidine) 
where rigorous safe handling guidelines have been available for many years and selected 
antibiotics which currently lack comparable guidance. This study also showed that the 
number of ribavirin respondents was relatively low compared to the other studied 
medications possibly indicating that ribavirin therapy has diminished.
Overall, survey findings showed that respondents who administered pentamidine were more 
likely to adhere to good work practices compared to those who administered antibiotics. 
Those who administered pentamidine were more likely trained, familiar with employer 
standard procedures, have engineering controls in place, and use eye/face protection and 
respirators. They were also less likely to touch various objects in the work area while 
wearing gloves that had been used to handle medications, but more likely to take home 
potentially contaminated clothing. Despite the longstanding availability of safe handling 
guidelines for pentamidine, adherence to these guidelines was not universal.
A quarter of respondents administering pentamidine were never trained. Of those who had 
received training, 66% reported that it was more than 12 months ago. Of those trained, a 
greater proportion of pentamidine respondents had received initial training but not annual 
refresher training when compared to respondents who administered antibiotics. The latter 
was unexpected since refresher training is specified in safe handling guidelines.15 There are 
no specific training guidelines for antibiotics; however, the OSHA Hazard Communication 
standard mandates initial training for all hazards in the workplace.28 Respondents who 
administered both pentamidine and antibiotics were more likely to be trained than those who 
administered antibiotics alone. It is very likely that the training on safe handling of 
pentamidine would be relevant to antibiotics.
Our findings show that 32% of respondents who administered antibiotics did not always use 
any of four engineering controls; raising concerns that respiratory therapists and others may 
be exposed to fugitive aerosols. Information regarding the concurrent use of multiple 
engineering controls and reasons for disuse was not collected which limits full interpretation 
of these findings.
Personal protective equipment should be worn to provide additional protection from 
exposure to aerosolized medications. Both the NIOSH and ASHP guidelines state that 
protective gloves and gowns should be worn while handling hazardous drugs.21, 24 
However, protective gloves and gowns were not always worn by over 20% and nearly 70% 
of respondents, respectively, while administering pentamidine. Also, a small percentage (3–
4%) of respondents who handled pentamidine and/or antibiotics reported reusing gloves 
which may result in exposure and/or contamination of work area. Additionally, respirators, 
eye and face protection should be worn when handling hazardous drugs.24 A previous study 
found that most workers did not wear respirators during the administration of pentamidine 
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when local exhaust ventilation is available.29 This survey also found that respondents report 
not using respirators when an engineering control is in place, but documented that there are 
many additional reasons respondents do not use respirators when administering pentamidine.
Barriers to using each type of PPE most reported by respondents who administered 
pentamidine and antibiotics (“not part of our protocol,” “skin exposure was minimal”) 
suggests a perception among respondents that aerosolized medications pose a minimal 
exposure risk, or that employers do not fully appreciate the potential adverse health effects 
associated with exposure to these drugs. The differences in reported reasons for not using 
PPE by respondents who administer pentamidine vs. antibiotics may be attributable to the 
presence of safe handling guidelines for hazardous drugs which currently only apply to 
pentamidine. The lack of information on potential synergistic effects of exposure to multiple 
medications, which are biologically active by nature, underscores a need for precautionary 
practices to minimize exposures.
This survey targeted a few of the many medications delivered as aerosols to patients. 
Without appropriate controls in place to minimize the likelihood of exposure to fugitive 
aerosols, respiratory therapists, nurses and others who administer these and other aerosolized 
medications may be exposed unnecessarily. Data from this survey indicate that not all 
employers and employees are handling pentamidine in accordance with OSHA guidelines. 
Although the antibiotics included in this study lack authoritative guidelines, prudence 
dictates that appropriate safe handling precautions be taken for antibiotics as well as other 
aerosolized medications. This comprehensive precautionary approach should minimize the 
risk of exposure to fugitive aerosols to healthcare practitioners and bystanders during care of 
patients receiving aerosol therapy.
The limitations of this survey have been described elsewhere.26 However, there are three 
limitations specific to this hazard module. First, information on impediments to using 
aerosol delivery equipment and engineering controls was not collected and is recommended 
for future studies. Second, the relatively low number of respondents administering ribavirin 
prohibited meaningful interpretation of those data. Last, demographic information was 
unavailable for approximately 10% of respondents who chose not to complete the core 
module.
CONCLUSIONS
Findings from this survey show that precautionary practices are not universally used during 
administration of aerosolized medications. Training, availability of employer standard 
procedures, and use of engineering controls and PPE were more prevalent for pentamidine 
than the targeted antibiotics, most likely because of the longstanding safe handling 
guidelines for hazardous drugs including pentamidine. However, adherence to precautionary 
guidelines for pentamidine was not universal which is concerning. Research is needed to 
determine whether aerosolized antibiotics pose a health risk to workers. Until then, a 
precautionary approach should apply. The most commonly reported barriers associated with 
not using PPE suggest that employers and healthcare workers are not aware of the hazards or 
believe that exposures are inconsequential or are so rare as to not warrant their use. 
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Employers and employees share responsibility for ensuring that precautionary measures, 
including development and adherence to relevant standard procedures, are taken to keep 
exposures to all aerosolized medications as low as practicable.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 4
Reasons for Not Always Wearing PPE When Administering Aerosolized Antibiotics and Pentamidine
Reason Antibiotics* n=290 %‡ Pentamidine n=191 %‡ P-value†
An engineering control was being used§ 8 27 < 0.01
Not part of our protocol 77 64 < 0.01
(Skin) exposure was minimal_ 29 31 0.62
No one else who does this work uses them 20 10 < 0.01
Not provided by employer 19 11 0.02
Not readily available in work area 20 11 0.01
Too uncomfortable or difficult to use 4 4 0.66
Cross contamination to other areas is not a concern¶ 3 5 0.49
Concerned about raising the patient's anxiety 1 2 0.39**
Other 21 13 0.01
*
Antibiotics include tobramycin, amikacin and colistin.
†
Unless otherwise stated, the chi-square test was used to calculate p-values.
‡
Percents add to more than 100 percent because respondents could select more than one reason.
§
This reason was not included as an option for protective gloves.
Response for eye/face protection and respirator was “exposure was minimal.”
¶
This reason was not included as an option for eye/face protection and respirator.
**
Fisher’s exact test was used to calculate p-value.
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Table 5
Non-Recommended Practices Associated with the Use of Protective Gloves
Practices While Wearing Protective Gloves Antibiotics* Percent Yes Pentamidine Percent Yes P-value†




Activity performed while wearing gloves used to administer aerosolized 
medications§
n=265‡ n=163‡
 Touch I.V. pump or bed controls 54 19 < 0.01
 Use pens/pencils 51 36 < 0.01
 Touch waste basket/garbage bags 28 22 0.18
 Touch door knobs, cabinets, or drawers 52 41 0.03
 Use of computer/calculator 34 23 0.01
 Handle files or charts 9 13 0.25
 Used a non-disposable stethoscope 50 36 < 0.01
 Use of phone/cell phone or pager 25 15 0.02
 Eat, drink, chew gum or smoke 5 3 0.45
 Use restroom 2 2 0.29_
 Apply cosmetics <1 1 0.47_
*
Antibiotics include tobramycin, amikacin and colistin.
†
Unless otherwise stated, the chi-square test was used to calculate p-values.
‡
Number of respondents varied for individual items (i.e., number of eligible respondents less number who elected not to answer).
§
Percents add to more than 100 percent because respondents could select more than one activity.
Fisher’s exact test was used to calculate p-value.
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